Piramal Pharma Lexington facility successfully completes USFDA Inspection
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-05-23 09:58 GMT | Update On 2024-05-23 09:58 GMT
Advertisement
Mumbai: Piramal Pharma Limited has informed in a recent BSE filing that the US Food and Drug Administration (US FDA) has issued an Establishment Inspection Report (EIR) for the manufacturing facility located at Lexington, USA and the Pre-Approval Inspection (PAI) has now been successfully closed by the US FDA.
US FDA had inspected the facility from 20th February, 2024 to 23rd February, 2024 and issued 2 observations.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.